Publications des scientifiques de l'IRD

Drancourt M., Cortaredona Sébastien, Melenotte C., Amrane S., Eldin C., La Scola B., Parola P., Million M., Lagier J. C., Raoult D., Colson P. (2021). SARS-CoV-2 persistent viral shedding in the context of hydroxychloroquine-azithromycin treatment. Viruses, 13 (5), 890 [12 p.].

Titre du document
SARS-CoV-2 persistent viral shedding in the context of hydroxychloroquine-azithromycin treatment
Année de publication
2021
Type de document
Article référencé dans le Web of Science WOS:000654571900001
Auteurs
Drancourt M., Cortaredona Sébastien, Melenotte C., Amrane S., Eldin C., La Scola B., Parola P., Million M., Lagier J. C., Raoult D., Colson P.
Source
Viruses, 2021, 13 (5), 890 [12 p.]
SARS-CoV-2 nasopharyngeal shedding contributes to the spread of the COVID-19 epidemic. Among 3271 COVID-19 patients treated at the Hospital University Institute Mediterranee Infection, Marseille, France from 3 March to 27 April 2020, tested at least twice by qRT-PCR, the median SARS-CoV-2 nasopharyngeal shedding duration was 6 days (range 2-54 days). Compared with short shedders (qRT-PCR positivity < 10 days), 34 (1.04%) persistent shedders (qRT-PCR positivity >= 17 days; mean +/- SD: 23.3 +/- 3.8 days) were significantly older, with associated comorbidities, exhibiting lymphopenia, eosinopenia, increased D-dimer and increased troponin (p < 0.05), and were hospitalized in intensive care unit in 17.7% vs. 1.1% of cases (p < 0.0001). Viral culture was positive in six persistent shedders after day 10, including in one patient after day 17, and no viral co-pathogen was detected in 33 tested patients. Persistent shedders received azithromycin plus hydroxychloroquine >= 3 days in 26/34 (76.5%) patients, a figure significantly lower than in short shedders (86.6%) (p = 0.042). Accordingly, mortality was 14.7% vs. 0.5% (p < 0.0001). Persistent shedding was significantly associated with persistent dyspnea and anosmia/ageusia (p < 0.05). In the context of COVID-19 treatment, including treatment with azithromycin plus hydroxychloroquine, the persistence of SARS-CoV-2 nasopharyngeal shedding was a rare event, most frequently encountered in elderly patients with comorbidities and lacking azithromycin plus hydroxychloroquine treatment.
Plan de classement
Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052]
Localisation
Fonds IRD [F B010081532]
Identifiant IRD
fdi:010081532
Contact